
The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.
In this study, 432 men with a median age of 55 were put on active surveillance. Historically, men under 60 have not been recommended for active surveillance due to risk of aggressive disease or progression.
At 5 years, 75% of men remained on active surveillance, and at 10 years, 55% of men remained on active surveillance.






